secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aurinia Pharmaceuticals Inc. (AUPH)
CIK:        0001600620
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001628280-23-000762
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aurinia reports preliminary Q4 net revenue $28.4M; LUPKYNIS patients up to 1,525
--------------------------------------------------------------------------------

- Preliminary Q4 2022 net revenue ~$28.4M, full-year net revenue ~$134.0M.
- Net product revenue Q4 ~$28.3M, full-year ~$103.5M; 2022 guidance achieved.
- LUPKYNIS patients on therapy at Dec 31, 2022: 1,525, up from 1,354 at Sep 30, 2022.
- Q4 patient start forms ~406, compared to 374 in Q3 2022.
- Reiterates 2023 net product revenue guidance of $120-140M; cash & investments ~$388.7M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1600620/000162828023000762/0001628280-23-000762-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1600620/000162828023000762/auph-20230106.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-000762

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer